Trial Profile
A phase II trial of Gemzar (gemcitabine) and Gleevec (imatinib mesylate) in patients with metastatic renal cell carcinoma.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Imatinib (Primary) ; Gemcitabine
- Indications Renal cancer
- Focus Therapeutic Use
- 17 Dec 2009 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 28 Aug 2007 Status change from in progress to completed.
- 14 Aug 2007 Status change from recruiting to in progress.